Relay Therapeutics Inc
NASDAQ:RLAY
Income Statement
Earnings Waterfall
Relay Therapeutics Inc
Revenue
|
60.9m
USD
|
Operating Expenses
|
-703.9m
USD
|
Operating Income
|
-643m
USD
|
Other Expenses
|
55.4m
USD
|
Net Income
|
-587.6m
USD
|
Income Statement
Relay Therapeutics Inc
Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
83
N/A
|
84
+1%
|
84
+1%
|
85
+1%
|
3
-96%
|
3
-17%
|
2
-19%
|
2
-16%
|
1
-19%
|
1
-14%
|
1
-21%
|
26
+2 645%
|
26
-1%
|
61
+138%
|
|
Operating Income | |||||||||||||||||||
Operating Expenses |
(84)
|
(94)
|
(102)
|
(117)
|
(138)
|
(155)
|
(310)
|
(335)
|
(356)
|
(388)
|
(271)
|
(296)
|
(301)
|
(339)
|
(367)
|
(379)
|
(399)
|
(704)
|
|
Selling, General & Administrative |
(14)
|
(15)
|
(18)
|
(26)
|
(39)
|
(47)
|
(55)
|
(57)
|
(57)
|
(61)
|
(64)
|
(65)
|
(66)
|
(70)
|
(72)
|
(75)
|
(75)
|
(133)
|
|
Research & Development |
(70)
|
(77)
|
(82)
|
(88)
|
(97)
|
(106)
|
(252)
|
(273)
|
(293)
|
(314)
|
(207)
|
(230)
|
(246)
|
(278)
|
(305)
|
(320)
|
(330)
|
(582)
|
|
Depreciation & Amortization |
0
|
(2)
|
(2)
|
(2)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
(3)
|
(12)
|
2
|
0
|
12
|
8
|
11
|
15
|
6
|
12
|
|
Operating Income |
(84)
N/A
|
(94)
-12%
|
(102)
-8%
|
(117)
-14%
|
(56)
+52%
|
(72)
-29%
|
(226)
-215%
|
(250)
-11%
|
(353)
-41%
|
(385)
-9%
|
(269)
+30%
|
(294)
-9%
|
(299)
-2%
|
(338)
-13%
|
(366)
-8%
|
(354)
+3%
|
(373)
-5%
|
(643)
-72%
|
|
Pre-Tax Income | |||||||||||||||||||
Interest Income Expense |
9
|
8
|
7
|
5
|
3
|
2
|
(11)
|
(11)
|
(11)
|
1
|
2
|
4
|
9
|
15
|
22
|
28
|
31
|
55
|
|
Total Other Income |
(0)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
0
|
0
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
|
Pre-Tax Income |
(75)
N/A
|
(86)
-14%
|
(95)
-11%
|
(112)
-17%
|
(52)
+53%
|
(70)
-33%
|
(236)
-239%
|
(261)
-10%
|
(364)
-39%
|
(384)
-5%
|
(267)
+30%
|
(290)
-9%
|
(291)
0%
|
(323)
-11%
|
(344)
-7%
|
(326)
+5%
|
(342)
-5%
|
(588)
-72%
|
|
Net Income | |||||||||||||||||||
Income from Continuing Operations |
(75)
|
(86)
|
(95)
|
(112)
|
(52)
|
(70)
|
(236)
|
(261)
|
(364)
|
(384)
|
(267)
|
(290)
|
(291)
|
(323)
|
(344)
|
(326)
|
(342)
|
(588)
|
|
Net Income (Common) |
(75)
N/A
|
(86)
-14%
|
(95)
-11%
|
(112)
-17%
|
(230)
-106%
|
(247)
-8%
|
(414)
-67%
|
(439)
-6%
|
(364)
+17%
|
(384)
-5%
|
(267)
+30%
|
(290)
-9%
|
(291)
0%
|
(323)
-11%
|
(344)
-7%
|
(326)
+5%
|
(342)
-5%
|
(588)
-72%
|
|
EPS (Diluted) |
-0.87
N/A
|
-0.98
-13%
|
-1.09
-11%
|
-1.56
-43%
|
-2.56
-64%
|
-2.74
-7%
|
-4.5
-64%
|
-4.73
-5%
|
-3.82
+19%
|
-3.54
+7%
|
-2.45
+31%
|
-2.61
-7%
|
-2.59
+1%
|
-2.65
-2%
|
-2.83
-7%
|
-2.66
+6%
|
-2.79
-5%
|
-4.49
-61%
|